Cleerly uses coronary CT analysis to quantify plaque and support clinical review

Cleerly applies AI-enabled analysis to coronary computed tomography angiography, or CCTA, to characterize coronary artery disease. Its products quantify plaque, assess vessel-level likelihood of ischemia and compare plaque findings over time. The practical question for a healthcare organization is how these measurements fit a qualified clinician’s interpretation, the imaging service and the follow-up process.

01 / ProductPlaque, ischemia and longitudinal comparison answer different questions

The Cleerly platform is presented as a web-based service for assessing coronary artery disease from CCTA. Its plaque analysis offering describes vessel-level detail, plaque volume and composition, and stenosis quantification. Those outputs describe different aspects of coronary anatomy; a single headline score would obscure the separate information a clinician needs to interpret.

Cleerly ISCHEMIA adds an AI-enabled assessment of a vessel’s likelihood of ischemia. The company’s explanation says a physician or another qualified healthcare professional then assesses the data to determine whether an intervention is needed. The software output is therefore part of a clinical decision process, rather than a stand-alone treatment instruction.

Cleerly COMPARE supports longitudinal assessment of plaque. The company describes an AI-generated report that a human reviewer reviews, refines and confirms. That is a meaningful workflow detail: comparison involves an analysis process around the model, not simply subtraction of two unexamined automated measurements.

The current official website resolves to cleerly.com, while some provider systems and older links retain cleerlyhealth.com. This is one active company identity. Its specific focus on quantitative coronary imaging makes it a relevant specialist AI company for coverage, without requiring an unsupported claim that it is the best choice for every cardiac imaging service.

02 / AudienceCardiac imaging teams must connect measurements with clinical context

Cleerly is relevant to cardiology practices, imaging centers and health systems evaluating quantitative coronary CT analysis. The clinical reader, the team acquiring the scan and the organization responsible for follow-up all have a role. A useful result depends on an appropriate input examination and an agreed path for reviewing and communicating the output.

The service is not a general-purpose image model that a consumer can use to decide whether to start or stop treatment. CCTA acquisition and clinical interpretation require qualified professionals. This blueprint explains the software offering and its operational implications; it does not establish who should receive a scan or how an individual patient should be treated.

Aidoc offers an adjacent perspective on clinical imaging AI and enterprise orchestration. Tempus describes another approach to connecting clinical data and precision medicine. Cleerly’s narrower proposition centers on coronary CT-derived information, so buyers should compare the specific imaging question and care process rather than treating these platforms as interchangeable.

A service already producing detailed CCTA reports may be interested in more standardized quantitative information or longitudinal comparison. A service without a reliable acquisition and review process has a more basic dependency to resolve. Purchasing an analysis tool does not create scanner capacity, clinical expertise or an appropriate patient pathway.

03 / WorkflowA proposed evaluation begins with an eligible scan and a qualified reader

For a proposed evaluation, select one clinical service and one Cleerly application. Obtain the current product documentation and have the responsible imaging team define which existing studies are eligible. Use appropriately authorized retrospective material and an established reference-review process. The purpose is to assess local fit before making claims about improved patient outcomes.

Examine the acquisition requirements before submitting a study. Cleerly’s imaging resources page offers vendor-specific scan and reconstruction protocols through a form. The underlying protocol files were not available in the open page reviewed for this article, so no scanner settings are invented here. The local team needs the actual current instructions.

Trace the study through submission and returned analysis. Verify patient and examination matching and inspect whether the required coronary regions can be assessed. Record incomplete or rejected studies as separate outcomes. An unavailable measurement is not equivalent to an absence of disease, and staff need a visible way to recognize that distinction.

Have the qualified reader review the source images together with the quantitative output. Focus on how plaque characterization and stenosis information are presented, how uncertainty is handled and how the final interpretation enters the existing report. The relevant question is whether the information improves the reader’s work without encouraging them to treat a software output as an unqualified conclusion.

If the service is evaluating ISCHEMIA, identify where its vessel-level assessment sits in the local decision process. The product explanation places the subsequent judgment with a physician or other qualified professional. The pilot should therefore observe how the output is reviewed and documented, rather than treating the presence of a result as an automatic instruction to intervene.

For COMPARE, inspect a suitable pair of studies and the human-reviewed report. Ask how the same coronary region is matched and how differences in acquisition or image quality affect interpretation. A measured change is useful only when the reviewer can understand whether the underlying examinations support a meaningful longitudinal comparison.

Finish by following the report to its clinical recipient. Can the receiving clinician find the relevant images and understand what the analysis did and did not establish? Document correction effort, unusable-study reasons and report availability alongside processing time. Sequenced has not run this evaluation or independently measured Cleerly’s diagnostic performance.

04 / PricingReimbursement information is not the software’s purchase price

Cleerly’s billing guidance publishes U.S. coding and Medicare reimbursement information. The current page distinguishes plaque-analysis and other billing contexts. These are reimbursement references, not a public subscription tariff or a universal out-of-pocket price for a patient.

The same guidance includes qualifications about coding, payment and payer coverage. A health system should therefore separate the vendor’s service charge, the cost of the CT examination, professional interpretation and any amount a payer may reimburse. Combining them into one advertised AI price would hide the actual commercial and clinical arrangement.

The public site uses a demonstration and contact route for organizational evaluation. A proposal should name the selected analysis, expected study volume, support and review responsibilities. The COMPARE page says its additional human review has no extra charge within that feature; that statement does not mean the entire service or underlying scan is free.

For a financial assessment, use the organization’s actual payer mix and current contracts, reviewed by its reimbursement team. A code’s existence does not guarantee payment for every patient, indication or site. This article intentionally avoids presenting a reimbursement figure as a universal revenue forecast or a recommendation for billing an individual case.

05 / DistinctionsQuantitative plaque information is a distinctive focus

Cleerly emphasizes characterizing plaque as well as narrowing of the coronary lumen. Its plaque product page separates vessel-level findings, composition and stenosis information. That focus gives a buyer a concrete way to assess the product: inspect the additional information supplied and how a clinician uses it in the report.

Longitudinal comparison adds a second dimension. A single study describes one examination, while COMPARE asks whether measurements across examinations can be meaningfully related. The company’s explicit human-review step is relevant because matching and interpretation deserve scrutiny alongside the automated calculation.

The website presents comparative clinical studies and strong performance claims. Those claims are not treated here as a general superiority finding. A prospective buyer should read the original study and examine its population, reference standard and product version. A study of one endpoint cannot by itself prove that a particular deployment prevents heart attacks or improves every patient’s outcome.

The strongest product distinction is therefore a defined set of quantitative outputs embedded in a professional workflow. Buyers can evaluate their usefulness without assuming that more measurements always mean a better decision. The information must be interpretable, relevant and available at the point where the clinical team needs it.

06 / QuestionsImage quality, intended use and coverage remain specific

Which studies can the supplied version analyze? Obtain the current instructions and confirm the supported acquisition and patient scope. This article describes the public product portfolio and does not infer blanket regulatory authorization across every product, region, scanner or use case. A U.S. reimbursement page is not evidence of international clinical availability.

How are unassessable segments represented? A clinician should be able to distinguish measured anatomy, uncertain output and regions outside the analysis. This is an evaluation question rather than a claim about a specific interface control. It matters because missing data can otherwise disappear into a polished report and create a misleading impression of completeness.

What does a change in plaque measurement mean for a particular patient? The software can supply information for review, but interpreting the result requires clinical context and attention to the comparability of the scans. An apparent change should not automatically be translated into treatment success, failure or a new management instruction.

Who resolves a disagreement with the report? Clarify the path for clinical questions, corrected inputs and review of a disputed measurement. The responsibility should be explicit between the imaging center, vendor and interpreting clinician. A technically delivered report is only one step in a complete clinical service.

07 / DecisionEvaluate the report as part of the cardiac imaging service

Cleerly is a relevant candidate for organizations seeking quantitative coronary CT information and structured longitudinal analysis. Begin with a specific application, eligible studies and a qualified clinical reviewer. Follow the result into the existing interpretation and follow-up process, where its practical usefulness can be assessed.

A wider rollout should rest on suitable image acquisition, understandable outputs and clear responsibilities. Keep software cost, reimbursement and clinical value as separate parts of the decision so none is used as a shortcut for proving the others.